JCC: Il-6 deficiency exacerbates IL-10 deficiency of colitis in mice and induces systemic inflammatory response

the !----, background and target interleukin 6 (IL-6) or its receptors are currently candidates for targeted biotherapy for inflammatory bowel disease (IBD)therefore, it is important to fully understand the effects of blocking IL-6study aims to explore the effects of IL-6 deficiency on IL-10-defective mice with IL-10 -/) spontaneous colitismethod researchers will produce IL-6 / IL-10 double defects ( IL-6 -/- / IL-10 -/) the intestinal inflammation of the colon mucous membrane in mice compared to wild typeresults were unexpected, and IL-6 -/- / IL-10 -/- mice exhibited more pronounced intestinal inflammation and earlier onset of disease, whether localized (colon and small intestine) or systemic (spleen swelling, ulcerative dermatitis), white blood cell growth, neutropenia and mononucleoblastationthe increase of IL-6 -// / IL-10-/-----mouse sphysic factors (IL-1 beta, IL-4, IL-12, IL-12, TNF alpha) and chemofactors (MCP-1 and MIG), but ifN-pyridine did not increaseconclusions in IL-10 -/- mice can significantly increase intestinal inflammation by inhibiting Treg / CTLA-4 and promoting the IL-1 beta/Th2 pathway, completeIL-6 blocking, double mutants show signs of severe systemic inflammation